Randall Fuerst
Optometrist · Roseville, CANPI 1902998966
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,803 of the $11,992 with a category attached, or 73.4%. 21 manufacturers reported payments, led by Alcon at 31.5% of the total. Reporting peaked in 2019 at $3,896 and has fallen 73.5% since, to $1,033 in 2025. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $65.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Sight Sciences, Inc.$2K
- Johnson & Johnson Vision Care, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$984
- Bausch & Lomb Americas Inc.$424
- Coopervision Inc.$305
- plus $2K from 15 others
Across 3 payments — averaging $1415.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Vision Care, Inc.$4K
What the payments were for
- Consulting fees$1,40012%
- Speaking & faculty fees$1,75015%
- Food & beverage$8,80373%
- Gifts$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 58 | $3,780 |
| Sight Sciences, Inc. | 12 | $2,303 |
| Johnson & Johnson Vision Care, Inc. | 34 | $2,081 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $984 |
| Bausch & Lomb Americas Inc. | 12 | $424 |
| Coopervision Inc. | 7 | $305 |
| Shire North American Group Inc | 2 | $248 |
| Novartis | 4 | $246 |
| Biotissue Holdings Inc. | 2 | $238 |
| Rxsight Inc | 2 | $217 |
| Dompe US, Inc. | 6 | $188 |
| Harrow Eye, LLC | 2 | $177 |
| Glaukos Corporation | 1 | $155 |
| Optos, Inc. | 2 | $129 |
| Apellis Pharmaceuticals, Inc. | 1 | $122 |
| LKC Technologies, Inc. | 1 | $103 |
| AbbVie(2 entities) | 4 | $91 |
| Tarsus Pharmaceuticals, Inc. | 5 | $87 |
| Oyster Point Pharma, Inc. | 3 | $58 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Precision 1$1,859
- TearCare$1,756
- DAILIES TOTAL1$1,750
- Acuvue$1,527
- ULTRA$562
- XIIDRA$372
- OMNI(R) SURGICAL SYSTEM (US)$288
- BIOTRUE ONE DAY$229
- RXSIGHT CONTACT LENS$217
- RXSIGHT INJECTOR CARTRIDGE$217
- RXSIGHT INJECTOR HANDPIECE$217
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$217
- LIGHT ADJUSTABLE LENS (LAL)$217
- iDoseTR$155
- Wavelight Refractive Suite$142
- VEVYE$138
- DAILIES$130
- Syfovre$122
- Multiple Brands Contact Lens$113
- TRYPTYR$111
How this compares
$11,992 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 20 | $14,975 |
| LumiganBimatoprost | 13 | $6,800 |
| Loteprednol Etabonate | 13 | $2,542 |
| Cevimeline Hcl | 12 | $773 |
| Latanoprost | 29 | $242 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo | $424 | $14,97520 claims |
| AbbVieLumigan | $91 | $6,80013 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $984 | $2,54213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in Roseville
- Aaron LechRoseville$100K
- Lisa HornickRoseville$35K
- Steve YoelinNewport Beach$4.1M
- Matthew GellerSpring Valley$3.5M
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
- Jason TuSan Diego$351K
- Scott SchachterPismo Beach$312K
- Alicia LauSan Diego$300K
- Vin DangBakersfield$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.